Cost-effectiveness of peginterferon α-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 8, 2007, Pages 631-638

  Veenstra, David L ^a   Sullivan, Sean D ^a   Dusheiko, Geoffry M ^d   Jacobs, Michael ^d   Aledort, Julia E ^b   Lewis, Gavin ^e   Patel, Kavita K ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b RAND CORPORATION   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^e ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Cost effectiveness; Hepatitis B; Lamivudine; Peginterferon 2a

Indexed keywords

ADEFOVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DATA ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HEALTH CARE COST; HEPATITIS B; HUMAN; LONG TERM CARE; MALE; MONOTHERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT DURATION; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; GREAT BRITAIN; HEALTH CARE COSTS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; LAMIVUDINE; MARKOV CHAINS; MODELS, ECONOMETRIC; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY;

EID: 34447556813     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3281108079     Document Type: Article

References (37)

1. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38:S158-S168.
2. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus update working party on chronic hepatitis B. Liver Int 2005; 25:472-489.
3. UK Health Protection Agency, 2004. Available at: http://www.hpa.org.uk/ hpa/board_meetings/docs_2004/040923/prog_hep.pdf (accessed 23/2/2006).
4. Hahne S, Ramsay M, Balogun K, Edmunds WJ, Mortimer P. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy. J Clin Virol 2004; 29:211-220.
5. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
6. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34:S1-S3.
7. Aggarwal R, Ranjan P. Preventing and treating hepatitis B infection. Br Med J 2004; 329:1080-1086.
8. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39:857-861.
9. EASL. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003; 38:533-540.
10. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722.
11. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126:81-90.
12. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B, Technology Appraisal 96, February 2006, available at www.nice.org.uk (accessed June 2006).
13. Leung N. Chronic hepatitis B - treatment with nucleoside analogues. Med J Malaysia 2005; 60:22-27.
14. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695.
15. NICE. Guide to the Methods of Technology Appraisal (Reference N0515). London: National Institute for Health and Clinical Excellence; 2004.
16. Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000; 17:409-427.
17. Orlewska E. The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland. Value Health 2002; 5:404-420.
18. Crowley S, Tognarini D, Desmond P, Lees M, Saal G. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002; 17:153-164.
19. Pwu RF, Chan KA. Cost-effectiveness analysis of interferon-alpha therapy in the treatment of chronic hepatitis B in Taiwan. J Formos Med Assoc 2002; 101:632-641.
20. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119:172-180.
21. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527-1532.
22. Lok A. Is it meaningful to pursue the safety of long-term lamivudine treatment in patients with chronic hepatitis B? (Author reply). Gastroenterology 2004; 126:1933.
23. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32:294-298.
24. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8:493-496.
25. Van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52:420-424.
26. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122:664-675.
27. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113:1660-1667.
28. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-865.
29. Wang CC, Kowdley KV. Built to last? Durability of lamivudine-induced seroconversion in patients with chronic hepatitis B. Gastroenterology 2004; 126:1917-1919.
30. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Southampton Health Technology Assessments Centre (SHTAC); 2005.
31. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. CHE Discussion Paper 172. York: York Centre for Health Economics, University of York; 1999.
32. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290:228-237.
33. Gish R, Chang T, De Man RA, Gadano A, Sollano J, Han KH, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (Abstract). Hepatology 2005; 42:267A.
34. Goodman Z, Dhillon A, Wu P, Gray F, Atkins M, Stevenson C, et al. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B (Abstract). J Hepatol 1999; 30 (Suppl 1):59.
35. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686.
36. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142:821-831.
37. Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg 2002; 65:110-111.